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Abstract: Selective estrogen receptor modulators (SERMs) were discovered in the mid-1900s in
connection with estrogen-related pathological conditions. They were developed to antagonize the
adverse effects of estrogen and have been shown to be effective against postmenopausal disorders
manifested by estrogen deficiency. Raloxifene (RAL), one of the most widely used SERMs, expresses
estrogen-like effects on bones, while it is found to be an antagonist on breast and uterus. RAL
has multiple beneficial effects throughout the body, including antioxidant and anti-inflammatory
properties, because of which it gains particular attention. Additionally, previous studies have revealed
that RAL is an efficient modulator of heme-oxygenase (HO) expression. HO, through its general
activity, participates in comprehensive cell defense processes, thus the induction of HO by RAL
administration indicates a major role in its therapeutic efficacy. In this review, we compile the current
knowledge about the overall metabolic, neurocognitive, and cardiovascular effects of RAL involving
the cytoprotective HO-system.
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1. Introduction
Estrogen plays a crucial role in the physiology of reproduction as well as in the metabolic balance.
It is also essential for the cardiovascular and nervous system and has a fundamental role in the growth
and the maintenance of bones. Women entering menopause tend to be more exposed to metabolic
syndrome (MS) due to the decreasing level of circulating estrogen. MS is considered to be one of
the most common metabolic disorders, the incidence of which is positively correlated with estrogen
deficiency. MS contributes to the development of cardiovascular diseases (CVDs) by changing the
lipid profile, increasing inflammation and the activity of inducible nitric oxide synthase (iNOS), thus
causing vascular inflammation. Heme oxygenase (HO) with its anti-inflammatory, antioxidant, and
antiapoptotic effects play a decisive role in the prevention of vascular inflammation [1]. The most
common HO isoform, the inducible HO-1 is a pillar of several cytoprotective processes triggered by
ischemia, hypoxia, or inflammation [2]. The menopause associated indispensable mediating role of
HO-1 in cardiovascular protection was proved formerly. Numerous studies corroborated the strong
correlation between HO and female sex hormones [3,4].
Several studies have confirmed that those women who received hormone replacement therapy
(HRT), were less likely to suffer from the aforementioned disorders; however, the results of the estrogen
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replacement therapies are controversial. While animal studies have confirmed the cardioprotective
effects of estrogen, human clinical studies did not provide clear results. Opinions are divided regarding
the ineffectiveness of the HRT. Some have suggested that the failure of clinical trials is due to the dose
of hormones and the combined use of estrogen and progesterone, as progesterone silences estrogen
receptors (ER) and stimulates progesterone receptor-mediated responses that are exactly the opposite
to the effects of estrogen. In animal studies, it has been also clarified that the expression of ERβ, ERα,
and G protein-coupled ER (GPR30) in the arteries are decreased, which may significantly diminish the
beneficial effects of estrogen [5].
Nonetheless, besides the conventional HRT, there is another approach to replace sexual hormones,
which is known as selective estrogen receptor modulator (SERM) based drug therapy. SERMs are
specific nonsteroidal molecules mediating estrogen-agonistic effects on several tissues (e.g., bones,
heart, skin) and estrogen-antagonistic effects on the uterus and breasts [6] (Figure 1). Tamoxifen was
the first SERM which was used to impede breast cancer; however, because of its proven agonist effect
in the uterus, it was soon associated with endometrial cancer. Due to the same side effects, multiple
SERMs such as toremifene and droloxifene were not considered definitively successful [6]. Raloxifene
(RAL), the best known second-generation SERM, was approved for the treatment of postmenopausal
osteoporosis and the prevention of breast cancer in the USA [7]. RAL, in particular, exhibits potential
cardiovascular benefits, such as the improvement of endothelial function and reduction of the
accumulation of cholesterol [8] and has many further positive impacts on metabolic parameters.
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2. Mechanism of Action of Raloxifene
Estrogen receptors ar expressed throughout the body including the heart, central nervous system,
musculoskeletal system, and the liver. Tw types of nuclear ER w re identified so far, amely ERα
and ERβ. Lately, a new group of ERs has been discovered which is membrane-associated and mostly
contains G-protein coupled receptors (e.g., GPR30) [9]. ERs have a specific molecule binding domain
to which several potential ligands can attach. After SERMs bind to the ERs by a ligand-dependent
molecular mechanism, the receptor undergoes a spontaneous dimerization, after which it is capable of
regulating gene transcription. Agonists have the ability to accrete coactivators to the aforesaid complex,
resulting in the activation of gene transcription. On the contrary, antagonists recruit corepressors, which
action leads to the inhibition of the transcription [10]. RAL, because of its antagonist effect on the breast
and the uterus, can be effective in the prevention of breast and endometrial cancer. Taking advantage
of its agonist function in bones, RAL is also used for the prevention and treatment of postmenopausal
osteoporosis for decades [11]. RAL was approved by U.S. Food and Drug Administration (FDA);
the conjugates derived from its metabolism did not show any toxicity, the risk–benefit ratio of the
long-term administration of RAL was proved to be favorable [12].
Biomolecules 2020, 10, 375 3 of 9
3. Importance of the HO System
Heme oxygenase is a key enzyme in the production of endogenous carbon monoxide (CO). In the
presence of P450 reductase and reduced nicotinamide adenine dinucleotide phosphate (NADPH),
it catalyzes the degradation of heme, which results biliverdin, ferrous iron (Fe2+), and CO [13];
(Figure 2).
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CO, through connecting the p38 mitogen-activated protein kinase (MAPK), displays an
antiapoptotic, cytoprotective effect in endothelial cells [14]. In addition, it also possesses
anti-inflammatory properties by modulating transcription factors and inflammatory pathways [15].
The accumulated CO in the tissues can reduce the production of inflammatory mediator molecules
such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1β, besides its
anti-inflammatory responses by increasing the expression of anti-inflammatory IL-10 [16].
Biliverdin, with the help of biliverdin reductase, can be transformed into bilirubin. By reducing
oxygen radicals, NADPH reductase, and adhesion molecules, bilirubin is proved to be protective
against oxidative mechanisms [17]. Bilirubin/biliverdin, thanks to their antioxidant properties, can
effectively counteract oxidative stress.
Three isoforms of HO have been discovered so far, the inducible HO-1 and two constitutive forms,
HO-2 and HO-3. In physiological conditions, HO-1 is expressed in all tissues and organs at a basal
level and can be induced by numerous factors, HO-2 occurs in almost all organs constitutively [18].
Although HO-1 expression is regulated at a transcriptional level, several kinase signaling cascades
can modulate the HO-1 promoter bounded transcription factor as a result of external stimuli. HO-1
expression is strongly affected by all three MAPK pathways including p38 MAPK [19]. In addition,
proinflammatory cytokines, such as TNF-α and IL-1α, can also enhance HO-1 expression via a protein
kinase-C – dependent (PKC) pathway [20]. Along with these, nuclear factor erythroid 2-related factor
2 (Nrf2) has been shown to induce the transcription of HO-1, while Bach1 is proved to be a potential
repressor [21–23]. With the regulation of HO-1 expression, Nrf2 and Bach1 are considered as key
factors in the regulation of cardiometabolic processes [24,25]. Diabetes and coronary artery diseases
are also associated with moderate signalization of Nrf2; moreover, it shows effective protection against
cardiomyocyte apoptosis [26]. These results are in line with the observations of Kato et al. therefore,
both HO-1 and HO-2 have an indispensable role in the cardioprotection; by applying enzymatic
inhibitors of HO, such as tin-protoporphyrin (SNPPIX) or zinc-protoporphyrin (ZnPPIX), a marked
aggravation in the ischemic reperfusion injury was observed [27–29].
The level of HO shows a strong correlation with aging processes. Aging is accompanied by
many biological mechanisms, such as the elevation of reactive oxygen species (ROS) and changes
in the lipid profile which are the main causes of cardiovascular morbidity. Before the occurrence of
menopause, women are more protected against CVD due to the presence of estrogen compared to
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age-matched men. Female sex hormones are proved to have both antioxidant and vasculoprotective
effects; moreover, estrogen has implications with the HO system. A previous study of our laboratory
confirmed, that decreased level of estrogen caused by ovariectomy led to a significant attenuation of
HO expression; however, with an exogenous estrogen supplementation, we were able to restore HO
expression in vivo [3]. We have found, consistent with the results of Sin-Ae et al., that just like estrogen,
RAL was also an efficient modulator of HO-expression and activity in the heart of female rats [4,30].
We have also proved that estrogen deficiency comes along with an elevated level of myeloperoxidase
enzyme (MPO) and inflammatory markers, although estrogen and RAL administration effectively
reduced these aforementioned parameters [4]. By and large, the increasing inflammation and oxidative
stress contribute to the development of CVD after menopause, therefore the application of hormone
therapy may promote the prevention of age-related cardiovascular pathological processes.
4. Cardiometabolic Effects of RAL
Several studies have confirmed the extensive cardioprotective effects of female sex hormones. It is
well known that estrogen can enhance NO production, thus contributing to the relaxation of blood
vessels and the reduction of blood pressure [31]. Moreover, it is also proved that estrogen effectively
reduces the size of infarction and the presence of ischemia-reperfusion injury in rat model [32]. RAL
was developed to counteract the proliferative effects of estrogen, but with its estrogen-like effects in the
cardiovascular system, it plays an important role in cardioprotection.
The coexistence of several risk factors is responsible for the development of heart diseases.
Abdominal fat mass, in particular, is associated with increased cardiovascular risk. Women after
menopause tend to suffer from visceral fat accumulation due to the estrogen deficiency caused positive
energy balance [33]; moreover, it also suggests that estrogen may play a central role in adipocyte
differentiation [34]. Numerous studies confirmed the weight-modulating effect of RAL [35,36].
Rodrigues-Junior et al. observed that 30-day RAL treatment evoked a significant weight loss in Wistar
rats [35], while human clinical studies showed that a 1-year RAL administration contributed to the
prevention of further accumulation of abdominal fat [37]. The underlying processes have so far been
unclear regarding the weight-regulating property of RAL, but a recent study proved that it may be
materialized by a fatty acid oxidation pathway in the liver [38].
Weight gain often results in disadvantageous changes in the lipid profile, thus redounding the
development of dyslipidemia. Dyslipidemia is a common metabolic disorder with elevated low-density
lipoprotein (LDL) and decreased level of high-density lipoprotein (HDL), therefore predisposing to the
development of atherosclerosis and ultimately to the appearance of CVD. In the postmenopausal stage,
RAL is proved to be efficient in reducing the level of LDL. In clinical studies, RAL has been shown to
significantly diminish total cholesterol content and LDL as well [39]; additionally, an animal study
with cholesterol-fed rabbits also demonstrated the cholesterol-lowering effect of RAL [40]. The authors
stated that RAL efficiently improved the lipid profile in postmenopausal women and in experimental
menopause including triglycerides and plasma LDL [39,40]. RAL is also able to influence endothelial
functions, together with its cholesterol diminishing effect, it clearly has a crucial role in the prevention
of atherosclerosis [41]. It has been shown to enhance vasomotor activity sustained by endothelium and
decrease the level of homocysteine after a 3-month-long treatment in postmenopausal women [42].
In a well-established in vivo atherosclerotic model, RAL was proved to reduce atherosclerosis in
ovariectomized rats [40]. In the progression of atherosclerosis, the presence of inflammatory processes
is also required. As previously described, HO-1 expression is partly regulated by pro-inflammatory
cytokines, which suggests its essential role in the prevention of atherosclerosis [1]. It is determined that
HO-1 overexpression was able to diminish the expression of inflammatory molecules and improved
aortic vasodilatation [43]. The presence of oxidized LDL enhances ROS production, which leads to the
upregulation of adhesion molecules in endothelial cells. Nrf2 is proved to attenuate endothelial cell
activation, thus diminish the expression of adhesion molecules [44]. In addition, Nrf2 pathways also
induce anti-inflammatory processes in endothelial cells [45]. These findings suggest the preventive
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effects of HO in the pathomechanism of atherosclerosis. HO-1 has been shown to have a protective
effect against endothelial cell abnormalities and vessel remodeling as well [46]. The byproducts of HO,
such as biliverdin and bilirubin, effectively prevent the peroxidation of LDL; thereby, elevated plasma
bilirubin content is associated with decreased atherogenic risk [47,48].
High blood pressure as a cardiovascular risk factor also contributes significantly to the progression
of atherosclerosis. The onset of menopause often entails higher blood pressure which can be explained
with the absence of estrogen. In one of our previous works, we found that surgical ovariectomy caused
estrogen deprivation significantly increased the blood pressure in rats; however, we demonstrated
that a 2-week-long administration of RAL reversed the estrogen absence caused raised blood pressure.
We also proved that ovariectomy (OVX) caused elevated arginine vasopressin (AVP) can be markedly
reduced by applying a two-week-long RAL treatment [4]. Hypertension evoked endothelial dysfunction
and hypertension is partly characterized by reduced endothelial NOS (eNOS) activity that resulted
in a decreased level of NO. Throughout a similar pathway, CO, the byproduct of HO activity, is also
capable of smooth muscle relaxation; therefore, it may play an important role in the maintenance of
endothelial function and the regulation of vasodilatation. By using spontaneously hypertensive rats,
it has been demonstrated that the induction of HO-1 led to the stabilization of blood pressure [49].
In the previously described work of ours, it has been also shown, that RAL treatment, similar to its
beneficial effects on the blood pressure, could enhance the HO expression not only in the heart but in
the aorta as well [4]. Interestingly, HO-2 expression was also promoted by estrogen, thus it suggests
that RAL may be one of the few potent activators of HO-2 [4,50]. Kawamura et al. confirmed that
the overexpression of HO-1 was able to restore the activity of eNOS in the endothelium [43]. Thereby,
the interplay between HO and NOS system might play a prominent role in the pathomechanism of
hypertension after menopause.
5. Effects of RAL in Neuroprotection
Female sex hormones with their extensive effects have a strong influence on neuronal processes
as well. Oxidative stress caused neuronal cell death as an age-related factor also affects women after
menopause. Oxidative stress is responsible for several pathological changes in the brain including the
oxidation of proteins and lipids.
Accumulating evidence has shown the antioxidant effects of RAL which has the most fundamental
importance in the brain [51,52]; together with the fact that HO-1 is found to reduce oxidative stress
and improve cognitive function in Alzheimer rat model [53], this supports RAL’s possible effectiveness
in the nervous system. RAL effectively reduces neuronal cell death by mitigating oxidative stress [54].
In an estrogen depleted rat model, RAL is found to decrease several oxidative stress markers, such as
malonaldehyde (MDA) and proved to enhance the antioxidant glutathione (GSH) level [55]. Moreover,
similar results were obtained in clinical studies involving postmenopausal women [56]. RAL exerts its
antioxidant effects partly via GPR30 pathway, through which phosphatidylinositol-3-kinase (PI3K)/Akt
and MAPK signalization will be activated. Both pathways play a central role in the lowering of
oxidative stress, ultimately in the neuroprotection by modulating antioxidant enzyme expression [41].
RAL also has a great impact on the anti-inflammatory mechanisms of the brain. Numerous studies
have revealed the pro-inflammatory cytokine (IL-6, TNF-α) diminishing properties of RAL, and it is
also clarified that RAL is capable of reducing the presence of reactive microglia in the brain. In cell
cultures, it also successfully decreased the IL-6 production of microglial cells [54–57], implying another
potential anti-inflammatory impact of RAL. All these findings suggest that RAL itself and by interacting
with the HO system, has neuroprotective effects in addition to its far-reaching favorable impacts.
6. Conclusions
Taken together, the overall metabolic, cardiovascular, and neuronal actions of RAL we can
enunciate its clinical importance (Figure 3.). Numerous studies have already confirmed its pivotal role
in the prevention of osteoporosis [58–60]; however, in this review, we approached its cardiometabolic
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and neuroprotective impacts. It has been shown that RAL has a potential therapeutic perspective in
the moderation of obesity, dyslipidemia, and endothelial dysfunction thus on reducing the occurrence
of atherosclerotic processes. Nonetheless, we cannot ignore its antioxidant and anti-inflammatory
effects incorporating the cytoprotective HO-system. Therefore, induction of HO-1 via RAL is a
promising strategy in the treatment of cardiac and neurological abnormalities. All things considered,
postmenopausal health maintenance should have crucial importance to prevent estrogen deprivation
elicited metabolic and vascular dysfunctions.
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